CD276 (B7-H3) Is an Immunotherapeutic Target in Acute Myeloid Leukemia with Preclinical Efficacy of Vobramitamab Duocarmazine, an Investigational CD276 Antibody-Drug Conjugate

vobramitamab duocarmazine (MGC018) - MacroGenics

https://ashpublications.org/blood/article/142/Supplement1/5958/504959/CD276-B7-H3-Is-an-Immunotherapeutic-Target-in

Danielle C Kirkey; Melia Blankenfeld; Tiffany Hylkema; Deryk Loo; Ashley Ward; Leila Robinson; Jack H Peplinski; Logan K Wallace; Laura Pardo; Andrew J. Menssen; Rhonda E Ries; Soheil Meshinchi

Dec 3, 2023